tbuckley/cabot-search huggingface dataset:
Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice
Authors: A. Drakaki, P. Luhn, H. Wakelee, P.K. Dhillon, M. Kent, J. Shim, V. Degaonkar, T. Hoang, V. McNally, S.Y. Chui, R. Gutzmer
Journal: Annals of Oncology (2019)
Comparison of three different radiation fractionation schedules in the palliation of painful bone metastasis.
Authors: Monica Malik, Swapna Jilla, Nanditha Sesikeran, K. V. Jagannath Rao Naidu, Suresh Pamidighantam, Venkata Ratnam Sunkavalli
Journal: Journal of Clinical Oncology (2012)

9055 Background: The purpose of this study was to compare the efficacy of a single fraction versus two multifractionated regimens in the palliation of painful bone metastases. Methods: Patients with painful bone metastases were randomized into three groups. Group I received a dose of 8 Gy in a single fraction, Group II received 20 Gy in five fractions and Group III patients received 30 Gy in 10 fractions. Pain score, ECOG performance status and analgesic requirement were recorded at baseline and at 1, 4, 8 and 12 weeks following treatment. Pain score was recorded on a 5-point verbal rating scale from 0 (no pain) to 4 (extremely severe pain). Overall response was defined as decrease in pain score by at least one point. Complete response was defined as achieving a pain score of zero at any point during follow-up. Duration of overall response was defined as the time from initial response till return of pain to its baseline value. Results: 45 patients were included with 15 in each group. Median age was 55 years (range 29-78 years). 17(37.7%) had metastasis in pelvic bones; 17(37.7%) in the spine while the remainder in the appendicular bones. Overall response rates in Groups I, II and III at week 1 were 60%, 53.3% and 60% respectively (p=0.71). At 1 month, overall response rates were 71.4%, 73.3% and 73.3% (p=0.84) and at 3 months; 78.5%, 80% and 80% respectively (p=0.86). The rate of complete response in all the three groups was 20%. Improvement in performance status in Groups I, II and III was seen in 60%, 66% and 80% respectively (p=0.69). Analgesic usage decreased in 86%, 87% and 80% patients in groups I, II and III respectively (p=0.66). Out of the nine complete responders, two sustained the response for less than four weeks, four patients up to eight weeks and remaining three till the end of follow-up. There was no statistically significant difference in between the three arms among all the variables compared. Conclusions: All three groups showed equal efficacy in pain palliation, analgesic requirement, improvement in performance status and duration of response. In patients with very advanced disease and short life expectancy, where the treatment goal is to decrease pain, 8 Gy in single fraction is a convenient and cost effective schedule.
The Caris registry: Building a biomarker-focused database to advance patient care.
Authors: Sheri Sanders, Wendy Schroeder, Alan Wright, Jeff Field
Journal: Journal of Clinical Oncology (2012)

e21152 Background: The medical community is continually searching for the best way to treat cancer. The value and utility of biomarkers in guiding treatment decisions is widely accepted but remains a challenge for the bedside clinician and requires ongoing validation and correlation to clinical outcomes. Caris Life Sciences has a dedicated team of scientists who study volumes of scientific literature, synthesize biomarker research and by way of an evidence-based electronic rules engine, translates the application of the literature to biomarker analysis of tumor tissue (The Target Now Report) in support of biomarker-drug association evidence useful in clinical decision-making. Subsequently, Caris initiated the Caris Registry to capture clinical disease, treatment and outcome data from patients who have a Target Now Report. Methods: The Caris Registry is a web-based data entry platform based on an IRB approved protocol. The eligible subject for the Registry will have a qualified Target Now Report. All clinical data elements are defined and supported by the NCI caBIG standardized data dictionary. Disease history/status, treatments and outcomes are captured at enrollment with Day 1 defined as the date of the Target Now Report and every 9 months for 5 years or death whichever is first. Results: As of January 19, 2012, there are 68 participating centers across the country and 43 centers pending IRB submission. There are 852 Target Now cases enrolled with the following cancer lineage distribution: Breast 209, Ovary 169, Lung 117, Colon 79, Endometrium 33, and other 245. There are 323 completed follow up reports and 175 completed end of study reports capturing vital status and cancer related deaths. Conclusions: Caris has successfully launched a scientifically valid and regulatory compliant Registry and database intended to become a robust library of tumor biomarker results linked to clinical outcomes data. As the library grows, data mining could provide vital information access to researchers, pharmaceutical firms, government, academia and insurers for use in drug development, molecular and biomarker research, economic impact assessments, healthcare policy discussion and most importantly directing personalized cancer treatment.
SyRI: finding genomic rearrangements and local sequence differences from whole-genome assemblies
Authors: Manish Goel, Hequan Sun, Wen-Biao Jiao, Korbinian Schneeberger
Journal: Genome biology (2019)

Genomic differences range from single nucleotide differences to complex structural variations. Current methods typically annotate sequence differences ranging from SNPs to large indels accurately but do not unravel the full complexity of structural rearrangements, including inversions, translocations, and duplications, where highly similar sequence changes in location, orientation, or copy number. Here, we present SyRI, a pairwise whole-genome comparison tool for chromosome-level assemblies. SyRI starts by finding rearranged regions and then searches for differences in the sequences, which are distinguished for residing in syntenic or rearranged regions. This distinction is important as rearranged regions are inherited differently compared to syntenic regions.
GP faces jail for sexually assaulting 23 female patients
Authors: Clare Dyer
Journal: BMJ (2019)

A London GP is facing jail after he was convicted of sexually assaulting 23 female patients by performing unnecessary intimate examinations for his own gratification.

Manish Shah was found guilty at the Old Bailey of nine counts of sexual assault and six counts of sexual assault by penetration relating to eight women, after a six week trial that ended on 3 December.

At an earlier trial, which concluded in December 2018 but could not be reported at the time, he was convicted of assaults on a further 17 women. He will be …
Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research
Authors: Omonigho M. Bubu, Andreia G. Andrade, Ogie Q. Umasabor-Bubu, Megan M. Hogan, Arlener D. Turner, Mony J. de Leon, Gbenga Ogedegbe, Indu Ayappa, Girardin Jean-Louis G, Melinda L. Jackson, Andrew W. Varga, Ricardo S. Osorio
Journal: Sleep Medicine Reviews (2019)
I Hope They Don’t Drop Me
Authors: Laura Davies Foley
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer of the urogenital tract: bladder cancer. Triple cystogram and selective arteriography
Authors: E. K. Lang
Journal: JAMA (1969)

The effectiveness of treatment of carcinoma of the bladder is based upon appropriate selection of a treatment modality which is specifically geared to the stage of infiltration and histologic differentiation of a given bladder tumor.<sup>1,4</sup>Clinical examinations, consisting of (1) bimanual examination with the patient under anesthesia, (2) cystoscopy, and (3) deep-muscle biopsy, have provided fairly accurate data for the staging and grading of bladder tumors.<sup>4,5</sup> Conventional roentgenographic examinations, such as cystograms, intravenous urograms, superimposition cystograms, and double contrast cystograms, are aimed at the demonstration of a mass lesion, but are ill-suited for differentiation of inflammatory from neoplastic disease.<sup>6,7</sup> Arteriography is a new technique which allows selective visualization of the tumor itself by demonstrating the characteristic abnormal vessels of the tumor.<sup>8-14</sup>Identification of abnormal vessels supplying the tumor allows accurate assessment of the size of the tumor; depth of penetration into the muscular wall of the
The prognostic value of tumour-infiltrating lymphocytes (TILs) in pancreatic cancer: A systematic review and meta-analysis
Authors: A. Orhan, R.P. Vogelsang, M.B. Andersen, M.T. Madsen, E.R. Hölmich, H. Raskov, I. Gögenur
Journal: Annals of Oncology (2019)
Abstract B38: Calcium signaling induces a partial EMT in pancreatic ductal adenocarcinoma
Authors: Robert J. Norgard, Ravikanth Maddipati, Nicole M. Aiello, David Balli, Jason R. Pitarresi, Derick N. Rosario-Berrios, Jinyang Li, Salina Yuan, Taiji Yamazoe, Yogev Sela, Allyson J. Merrell, Maximilian D. Wengyn, Kathryn Sun, Anil K. Rustgi, Ben Z. Stanger
Journal: Cancer Research (2019)

Abstract Metastasis and chemoresistance—the two main reasons for the high mortality of cancer—are associated with a form of cellular plasticity known as epithelial-to-mesenchymal transition (EMT). Cancer cells undergoing EMT become invasive, facilitating metastasis, and undergo a shift in their vulnerability to antineoplastic drugs. In recent work, it has been shown that EMT does not involve a single mechanism but rather a diversity of programs, yielding a continuum of cell phenotypes along the epithelial-mesenchymal spectrum. We previously developed a lineage-traced model of pancreatic ductal adenocarcinoma (PDA) to study EMT in the context of stochastically-arising tumors. As expected, epithelial-mesenchymal plasticity in some tumors involves transcriptional repression of the epithelial state, resulting in a “classical EMT” (C-EMT) phenotype. Surprisingly, however, epithelial-mesenchymal plasticity in the majority of tumors involves post-transcriptional repression of the epithelial state, resulting in a “partial EMT” (P-EMT) phenotype. These two plasticity programs are associated with other aspects of tumor biology as well, including distinct modes of cellular invasion. Here, we identify calcium signaling in pancreatic cancer cells as a regulator of the P-EMT phenotype. Prolonged calcium flux induces PDA cells to remove E-cadherin (ECAD) and other epithelial proteins from the surface and relocalize it intracellularly. This loss of the epithelial phenotype occurs without changes in the abundance of mRNAs for these proteins, reminiscent of the P-EMT phenotype observed in tumors in vivo. In addition, inhibition of the calcium-signaling protein calmodulin blunts this EMT-inducing effect. These results implicate calcium signaling as a mediator of partial EMT phenotypes. Citation Format: Robert J. Norgard, Ravikanth Maddipati, Nicole M. Aiello, David Balli, Jason R. Pitarresi, Derick N. Rosario-Berrios, Jinyang Li, Salina Yuan, Taiji Yamazoe, Yogev Sela, Allyson J. Merrell, Maximilian D. Wengyn, Kathryn Sun, Anil K. Rustgi, Ben Z. Stanger. Calcium signaling induces a partial EMT in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr B38.
GMC review of doctors’ wellbeing fails to recognise SAS doctors
Authors: Cathy Wield
Journal: BMJ (2019)

The GMC report Caring for doctors, caring for patients— which looks at doctors’ wellbeing and includes recommendations for strategies to mitigate against burnout — is commendable, particularly because it avoids the trap of putting more pressure on an already overburdened workforce.12

There are, however, certain noticeable deficiencies in its recommendations. Many workplace factors can only …
Image Gallery: Haematogenous metastasis of melanoma mimicking lymphangioma
Authors: A. Docampo‐Simón, M.J. Sánchez‐Pujol, I. Belinchón‐Romero, M. Niveiro, J. Bañuls
Journal: British Journal of Dermatology (2019)

Funding sources: none. Conflicts of interest: none to declare. Dear Editor, A 70‐year‐old man presented with a 3‐week history of multiple papules, which were vascular in appearance, on his trunk (a); 10 years previously he had undergone complete excision of a superficial spreading malignant melanoma from his abdomen. (b) On polarized light dermoscopy, the papules showed an angioma‐like pattern,1 with translucent‐to‐pink pseudolagoons, white lines and a hypopyon sign reminiscent of that classically described in lymphangioma (arrow).2 Polymorphous atypical vessels inside the pseudolagoons were also observed (arrowhead). (c, d) These pseudolagoons corresponded to nests of atypical melanocytes accompanied by prominent neovascularization [haematoxylin and eosin (HE) staining]. To our knowledge, this lymphangioma‐like pattern has not been described before in melanoma metastasis. ...
Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA)
Authors: Jennifer Tsai, Kelsey R. Logas, Lauren D. Van Wassenhove, Beruh Dejene, Che-Hong Chen, Daria Mochly-Rosen, Kenneth I. Weinberg
Journal: Blood (2019)
Association of asthma and smoking with lung function impairment in adolescence and early adulthood: the Isle of Wight Birth Cohort Study
Authors: S. Hasan Arshad, Claire Hodgekiss, John W. Holloway, Ramesh Kurukulaaratchy, Wilfried Karmaus, Hongmei Zhang, Graham Roberts
Journal: European Respiratory Journal (2019)

We investigated associations of asthma and smoking with lung function and airway reversibility from childhood to early adulthood.The population-based Isle of Wight Birth Cohort (n=1456) was assessed at birth, and at 1, 2, 4, 10, 18 and 26 years. Asthma was defined as physician diagnosis plus current wheeze and/or treatment. Spirometry was conducted at 10 (n=981), 18 (n=839) and 26 years (n=547). Individuals were subdivided into nonsmokers without asthma, nonsmokers with asthma, smokers without asthma and smokers with asthma, based on asthma and smoking status at 26 years. Their lung function trajectories from 10 to 26 years were examined using longitudinal models.Nonsmokers with asthma had smaller forced expiratory volume in 1 s (FEV1), FEF25-75% (forced expiratory flow at 25-75% of forced vital capacity (FVC)) and FEV1/FVC ratio compared to nonsmokers without asthma at age 10 and 18 years, with differences reduced after bronchodilator (pre-bronchodilator FEV1 at 26 years 3.75 L versus 4.02 L, p<0.001; post-bronchodilator 4.02 L versus 4.16 L, p=0.08). This lung function deficit did not worsen after 18 years. Smokers without asthma had smaller FEF25-75% and FEV1/FVC ratio (but not FEV1) at 26 years compared to nonsmokers without asthma, with the deficit appearing after 18 years and persisting despite bronchodilator response (for FEV1/FVC ratio at 26 years 0.80 versus 0.81, p=0.002; post-bronchodilator 0.83 versus 0.85, p=0.005). Smokers with asthma had worse lung function compared to other groups.Lung function deficits associated with asthma and smoking occur early in life. They are not fully responsive to bronchodilators, indicating a risk for long-term lung health, which highlights the need to institute preventive measures in adolescence and early adult life before irreversible damage occurs.
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia
Authors: Klaartje Somers, Kathryn Evans, Leanna Cheung, Mawar Karsa, Tara Pritchard, Angelika Kosciolek, Angelika Bongers, Ali El-Ayoubi, Helen Forgham, Shiloh Middlemiss, Chelsea Mayoh, Luke Jones, Mahima Gupta, Ursula R. Kees, Olga Chernova, Lioubov Korotchkina, Andrei V. Gudkov, Stephen W. Erickson, Beverly Teicher, Malcolm A. Smith, Murray D. Norris, Michelle Haber, Richard B. Lock, Michelle J. Henderson
Journal: Leukemia (2019)
Elephant in the room: how much pain is ok? If physiotherapy exercise RCTs do not report it, we will never answer the question
Authors: Benjamin E Smith, Henrik Riel, Bill Vicenzino, Chris Littlewood
Journal: British Journal of Sports Medicine (2019)

> Different therapists have said different things [contradictory advice on pain with exercise]…and it makes you wonder which therapist to believe.

Exercise is a proven treatment for managing at least some persistent pain, including musculoskeletal-related pain.1 2 But an area often overlooked is what type of pain and what intensity of pain should be associated with exercise. What would achieve the best results? No pain? A little pain? A moderate amount of pain? How does the patient judge what is ‘a little’ or ‘moderate’? How much pain is too much? Is there ‘good pain’ as patients often tell us when stretching or massaging a muscle, as well as ‘bad pain’ (presumably thought to be harmful)?

Qualitative research tells us that many individuals with persistent pain are uncertain when it comes to pain and exercise.3 4 This is closely linked to pain-related fear and questions as to whether exercise is helpful or harmful. As one patient framed it, ‘Are you making it worse? And that’s the crux of it really…if this is hurting should I really be doing this?’.3

There are few …
Bone marrow‐derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4‐year follow‐up of the MSC‐HF trial
Authors: Anders B. Mathiasen, Abbas A. Qayyum, Erik Jørgensen, Steffen Helqvist, Klaus F. Kofoed, Mandana Haack‐Sørensen, Annette Ekblond, Jens Kastrup
Journal: European Journal of Heart Failure (2019)
Putting Continuous Glucose Monitoring to Work for People With Type 1 Diabetes
Authors: Korey K. Hood, Linda A. DiMeglio, Matthew C. Riddle
Journal: Diabetes Care (2019)

The recent development of reliable systems for continuously monitoring interstitial glucose levels has set the stage for a revolution in diabetes research and care. The ability to obtain real-time and summary displays of glycemic patterns of individuals with diabetes, together with rapidly obtained agreement on various definitions and ways of handling the resulting data (1,2), has led to both rapid acceptance of continuous glucose monitoring (CGM) devices and incorporation of CGM into clinical research studies.

At the clinical level, some practical and quality-of-life–related benefits of CGM are well documented (3,4). Newer systems offer improved accuracy, fewer (or no) fingersticks, and remote monitoring of potentially dangerous glycemic events. While access to and use of CGM are increasing, some important questions remain. Which groups of people with diabetes will benefit the most from CGM use? When is the best time to introduce CGM systems to diabetes care? How should use of CGM systems be taught and adjusted? What specific outcomes are most critical to improve and document? How can this technology be used most cost-effectively? All members of the diabetes community—people with diabetes themselves, caregivers of persons with diabetes, diabetes care providers, payers, and health system managers—will benefit from objective data addressing all these questions. The collection of articles presented in this issue of Diabetes Care offers information on some of these questions for people with type 1 diabetes.

Three reports describe CGM experiences in diverse populations. Miller et al. (5) display the recent dramatic increases in CGM use by both youth and adults with type 1 diabetes in the T1D Exchange in the U.S. (6) and the DPV (Diabetes Patienten Verlaufdocumentation) registry in Germany and Austria (7). CGM use among those <18 years old increased from <5% in 2011 to 31% in the T1D Exchange and 44% …
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Authors: Aleix Prat, Cristina Saura, Tomás Pascual, Cristina Hernando, Montserrat Muñoz, Laia Paré, Blanca González Farré, Pedro L Fernández, Patricia Galván, Núria Chic, Xavier González Farré, Mafalda Oliveira, Miguel Gil-Gil, Miriam Arumi, Neus Ferrer, Alvaro Montaño, Yann Izarzugaza, Antonio Llombart-Cussac, Raquel Bratos, Santiago González Santiago, Eduardo Martínez, Sergio Hoyos, Beatriz Rojas, Juan Antonio Virizuela, Vanesa Ortega, Rafael López, Pamela Céliz, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá
Journal: The Lancet Oncology (2019)
Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice
Authors: Ping Li, Xinyu Yang, Yang Yang, Huamei He, Chon-Kit Chou, Fengyang Chen, Hong Pan, Lanlan Liu, Lintao Cai, Yifan Ma, Xin Chen
Journal: Journal of Controlled Release (2019)
The Mentalizing Approach to Psychopathology: State of the Art and Future Directions
Authors: Patrick Luyten, Chloe Campbell, Elizabeth Allison, Peter Fonagy
Journal: Annual Review of Clinical Psychology (2020)

Mentalizing is the capacity to understand others and oneself in terms of internal mental states. It is assumed to be underpinned by four dimensions: automatic-controlled, internally-externally focused, self-other, and cognitive-affective. Research suggests that mental disorders are associated with different imbalances in these dimensions. Addressing the quality of mentalizing as part of psychosocial treatments may benefit individuals with various mental disorders. We suggest that mentalizing is a helpful transtheoretical and transdiagnostic concept to explain vulnerability to psychopathology and its treatment. This review summarizes the mentalizing approach to psychopathology from a developmental socioecological evolutionary perspective. We then focus on the application of the mentalizing approach to personality disorders, and we review studies that have extended this approach to other types of psychopathology, including depression, anxiety, and eating disorders. We summarize core principles of mentalization-based treatments and preventive interventions and the evidence for their effectiveness. We conclude with recommendations for future research.